SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMs)
Copyright © 2001 by the New York Academy of Sciences
description
Annals of the New York Academy of Sciences 949:251-258 (2001)
© 2001 New York Academy of Sciences
The Effect of Selective Estrogen Receptor Modulators on Parameters of the Hypothalamic-Pituitary-Gonadal Axis
LEO PLOUFFE, JR. AND
SURESH SIDDHANTI
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46284, USA
Address for correspondence: Leo Plouffe, Jr., M.D., C.M., Medical Director, U.S. Women's Health and Reproductive Medicine, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285. Phone: 317-277-6284; fax: 317-277-3743.
lplouffe{at}lilly.com
The SERMs currently in clinical practice or in late stages of clinical development have been studied primarily for their effects on the breast, cardiovascular, bone, and reproductive systems. The effect of SERMs on the hypothalamic-pituitary-gonadal (HPG) axis has not been the primary focus of the studies conducted thus far. However the effect of SERMs on the HPG axis and the associated regulation of endocrine parameters may play an important role in their overall clinical profile. In this review the effects of selected SERMs on the HPG axis in premenopausal women, postmenopausal women, and men are summarized.
Key Words: selective estrogen receptor modulators • hypothalamic-pituitary-gonadal axis • premenopause • postmenopause • males
| 
